TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Feasibility of Participants Completing FIT Screening Tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of FIT Specimens Adequate for Lab Processing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Participants with Positive FIT Results Who Comply with Follow-up for Colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of Participants Who Feel FIT is an Acceptable Method of Screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median overall survival time (mOS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in level of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: E-mage Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak expiratory flow (PEF) value before first aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak expiratory flow (PEF) value after first aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak expiratory flow (PEF) value after second aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak expiratory flow (PEF) value after third aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of propofol required in mg/kg/hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early catheter removal failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Creatine Kinase (CK) Reflecting Worsening of Muscle Involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Bilirubin Representing Liver Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of ureteral stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of intraoperative neuromontoring alerts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ECG QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diurnal cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Severe Malaria Meeting Case Definition 1
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Severe Malaria Meeting Case Definition 2
Endpoint domain: Adverse events/effects
Primary endpoint: amount of p50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathogen Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FEV1 absolute values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Head Circumference Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment of scalp psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of parasitaemia in P. falciparum infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence of parasitaemia in P. vivax infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preterm Birth Before 37 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of PET activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort Immediately After Dosing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in oral steroid therapy requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in agitation from baseline to 2 hours post-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Malignant Alteration of Epithelial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Parietal Cell Protrusion/Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Foveolar Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Enterochromaffin-like-cell Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With G-cell Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite percentage of children appropriately treated for malaria, diarrhea, and pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 1323495 in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 1323495 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in modified bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of New Onset Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of SS-RBX in treating SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported initiation of LARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lung ultrasound changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effect size concentration of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Study Drug-associated Adverse Events Leading to Dose Holds or Reductions
Endpoint domain: Adverse events/effects
Primary endpoint: Count of Participants With Related Serious Adverse Events (SAEs) by NCI Common Toxicity Criteria v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Genotype of HR-HPV 16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Genotype of HR-HPV non 16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of laboratory diagnosed thrombophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis of AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptions of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HRSD reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of community-acquired pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Procedural Success of Endovascular PAD Treatment(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Success of Endovascular PAD Treatment(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Freedom From Major Adverse Events (MAEs) at One (1) and Three (3) Years
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking Topography- Puff Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Topography- Carbon Monoxide Boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Rating of Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic Yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hours to First Antibiotic Modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow of the Achilles tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time from TOF of 25% to 90% after 2 mg/kg sugammadex injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time from TOF of 100% to 0% after 0.6 mg/kg rocuronium injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time from TOF of 0% to 25% after orotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sugammadex effects on respiratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative Verbal Pain Score With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Remained Stable Annually for 4 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to edoxaban
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiogram (EEG) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal Detrusor Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of conjunctival bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of Fluocinolone Acetonide in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Fluocinolone Acetonide in Aqueous Humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF free, off all Class I and III Anti Arrhythmic Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention in the cohort
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Use of PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Avibactam and Ceftazidime in ELF and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of active phase of first stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Response to Targretin Gel 1% treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of Targretin Gel 1% treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in EuroQol 5D (EQ-5D) Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Assessment and management of gait, strength and balance deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of AZD5363
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With an IFN Alpha Signature Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting state EEG measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor task EEG measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Imagery task EEG measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Circulating tumor DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: base deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic Blood Pressure in Orthostatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Eating behaviour 1 - Daily Snacking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Eating behaviour 2 - Quantity of calories intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean 24-hour average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of condom use and chlamydia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes toward condom use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavior relating to condom use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in Dizziness Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deformity (degrees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (SF36 questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systemic Tumor Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in endothelial function assessed by flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical success / failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived visual functioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in perceived handicap due to hearing impairment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in overall condition of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of primary biliary cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Renal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of a virion-bound protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Hypertension Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Short Form 12 Health Survey (SF12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wound Dehiscence or Re-closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: re-infection prevalence and intensity of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with glycemic regimen de-prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Self-Reported Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: number of samples taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visits to high-cost care settings
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: hunger/fullness 120 minutes postprandial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of days alive without coma and delirium in the ICU
Endpoint domain: Mortality/survival
Primary endpoint: AUCt: Area under the drug concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Peak concentration of DWP14012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment toxicities: neuritis
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed responses: Complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Oxygen Consumption (VO2 Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone-Graft material integration score to host bone in the alveolar bone core
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: P2Y12 reaction units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HIV-1 DNA levels in CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comparative bioavailability of tablet formulation of AZD2281
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean serum conjugated bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Assisting Hand Assessment (AHA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time in Minutes of mask-on Positive Airway Pressure (PAP) Machine Usage Per Night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of deaths during hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Sputum bacterial clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of ophthalmological disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pain Scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Covid-19 viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of residual cancer burden class 0 and 1 (RCB0/1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DAT occupation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of difficult airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Goal Attainment Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Epistaxis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: development of a radiographic lymphocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of radiographic lymphoceles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of postoperative drainage catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Performance evaluation by health care professionals
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Performance evaluation by non-laboratory users
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of Time With Blood Glucose in Range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recollection
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC0-inf of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Ethinyl Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects with greater than or equal to 20% improvement in Arthritis Signs and Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Best-corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical silent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short interval cortical inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-cortical facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in topographical corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes